MedPath

Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

Phase 2
Completed
Conditions
Vestibular Schwannoma
Interventions
Device: YELLOW560 filter
Registration Number
NCT04351373
Lead Sponsor
Mayo Clinic
Brief Summary

The purpose of this study is to see if there is benefit to using an IV contrast called AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Fluorescein sodium (FS) and YELLOW 560 nm microscope filter (YE560) during surgeryYELLOW560 filterSubjects undergoing clinically planned vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma, removal surgery will have contrast agent fluorescein sodium administered intravenously after tumor exposure, and a special filter called YELLOW560 will be used on the operating microscope to see the fluorescent coloring of the contrast.
Fluorescein sodium (FS) and YELLOW 560 nm microscope filter (YE560) during surgeryFluorescein SodiumSubjects undergoing clinically planned vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma, removal surgery will have contrast agent fluorescein sodium administered intravenously after tumor exposure, and a special filter called YELLOW560 will be used on the operating microscope to see the fluorescent coloring of the contrast.
Primary Outcome Measures
NameTimeMethod
Surgeon Predicted Use of Fluorescein Sodium in Future CasesApproximately 3 months postoperatively

Physician response to surgeon survey question, "Based on the use and performance of FS in this case alone, how likely are you to use FS in future cases (excluding the research trial) involving this tumor?" using a Likert-style rating from 0-4 where 0=Unsure; 1= Plan to not use in any cases; 2= Plan to use in select cases; 3=Plan to use in the majority of cases; 4=Plan to use in all cases.

Correlation of Fluorescein Sodium With Surgeons' Visual AssessmentIntraoperatively, approximately 1 day

Fluorescence correlate with surgeons' visual assessment of the tumor and nerve tissue under normal microscopy without the Yellow 560 filter using a Likert-style rating from 1-4 where 1=No correlation; 2=Some correlation; 3=Good correlation; 4=Excellent correlation.

Correlation of Fluorescein Sodium With ElectrostimulationIntraoperatively, approximately 1 day

Surgeons' assessment of fluorescence correlate with electrostimulation (e.g. tissues with high fluorescence do not stimulate, whereas nerve tissues with low fluorescence do stimulate)" using a Likert-style rating from 1-4 where 1=No correlation; 2=Some correlation; 3=Good correlation; 4=Excellent correlation.

Secondary Outcome Measures
NameTimeMethod
Time to Differential VisualizationIntraoperatively, approximately 1 day

The amount of time in minutes for differential visualization of the tumor and surrounding tissue after sodium fluorescein administration during surgery

Average Dose of Sodium Fluorescein AdministrationIntraoperatively, approximately 1 day

Average dose of sodium fluorescein administered during surgery to achieve differential fluorescence of the tumor and tissue reported in mg/kg

Total Resection RateIntraoperatively, approximately 1 day

Number of subjects to have a gross total resection

Trial Locations

Locations (1)

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath